ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

January 10, 2003

Califano Insists On Search Committee To Look for NCI Chief; Brown Still In Running

February 25, 1977

NCi Advisors Approve New SPORE Grant Program In Cancer Communications.

December 1, 2000

In Brief: Fishman La Jolla President Emeritus, Ruoslahti Succeeds Him; Ariz. Seeks Meyskins Replacement

January 13, 1989

FDA Approves Arranon For Leukemia And Lymphoma

December 30, 2005

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001